CN100393866C - 减毒活寄生虫疫苗 - Google Patents

减毒活寄生虫疫苗 Download PDF

Info

Publication number
CN100393866C
CN100393866C CNB038222086A CN03822208A CN100393866C CN 100393866 C CN100393866 C CN 100393866C CN B038222086 A CNB038222086 A CN B038222086A CN 03822208 A CN03822208 A CN 03822208A CN 100393866 C CN100393866 C CN 100393866C
Authority
CN
China
Prior art keywords
parasite
live attenuated
gene
parasites
tet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038222086A
Other languages
English (en)
Chinese (zh)
Other versions
CN1681842A (zh
Inventor
N·F·J·范泊佩尔
A·N·沃梅伦
T·C·沙普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Akzo Nobel NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV, Akzo Nobel NV filed Critical Intervet International BV
Publication of CN1681842A publication Critical patent/CN1681842A/zh
Application granted granted Critical
Publication of CN100393866C publication Critical patent/CN100393866C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038222086A 2002-09-20 2003-09-19 减毒活寄生虫疫苗 Expired - Fee Related CN100393866C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078953 2002-09-20
EP02078953.3 2002-09-20

Publications (2)

Publication Number Publication Date
CN1681842A CN1681842A (zh) 2005-10-12
CN100393866C true CN100393866C (zh) 2008-06-11

Family

ID=32011015

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038222086A Expired - Fee Related CN100393866C (zh) 2002-09-20 2003-09-19 减毒活寄生虫疫苗

Country Status (8)

Country Link
US (1) US20050244437A1 (enExample)
EP (1) EP1543028A2 (enExample)
JP (1) JP2006518184A (enExample)
CN (1) CN100393866C (enExample)
AU (1) AU2003270274B2 (enExample)
BR (1) BR0313994A (enExample)
CA (1) CA2498604A1 (enExample)
WO (1) WO2004026903A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004309380B2 (en) 2003-12-19 2010-04-29 Seattle Biomedical Research Institute Live genetically attenuated malaria vaccine
US7722860B2 (en) 2004-12-03 2010-05-25 Seattle Biomedical Research Institute Live genetically engineered protozoan vaccine
ES2319242B1 (es) 2005-12-23 2009-12-01 Laboratorios Hipra, S.A. Aislado avirulento de neospora canimum y sus usos.
US9265818B2 (en) * 2007-05-04 2016-02-23 The United States Of America, As Represented By The Secretary Of Agriculture Genetically modified Babesia parasites expressing protective tick antigens and uses thereof
ES2326770B1 (es) 2007-07-13 2010-07-26 Universidad Complutense De Madrid Uso de un nuevo aislado de neospora caninum para el desarrollo de pruebas de diagnostico y para la fabricacion de productos para el tratamiento y prevencion de la infenccion causada por neospora.
RU2525587C2 (ru) * 2008-05-29 2014-08-20 Интервет Интернэшнл Б.В. Вакцинная композиция для иммунизации животного против кокцидиоза и способ ее использования
MX2011005133A (es) * 2008-11-13 2011-08-04 Intervet Int Bv Vacuna contra eimeria para pavos.
CN102483413A (zh) * 2009-07-13 2012-05-30 热体实验室有限公司 使用核糖体蛋白提取物（rpe）的寄生虫病如利什曼病的诊断
EP2412382A1 (en) 2010-07-29 2012-02-01 University Court of the University of Edinburgh Recombinant Trypanosoma theileri parasite
US20130224249A1 (en) * 2010-09-03 2013-08-29 Ludwig Institute For Cancer Research Ltd. Recombinant trypanosoma cruzi cells useful as anti-cancer immune agents
US20130287786A1 (en) 2010-12-29 2013-10-31 Theodorus Petrus Maria Schetters Canine babesiosis vaccine antigen
US10864260B2 (en) 2015-10-28 2020-12-15 Universidad Complutense De Madrid Neospora vaccine composition
EP3478301A4 (en) 2016-06-29 2020-04-22 Ramot at Tel-Aviv University Ltd. Manipulated parasites for the delivery of protein to the central nervous system (CNS)
WO2019140136A1 (en) * 2018-01-10 2019-07-18 University Of Washington Malarial vaccination methods and regimens
JP7032965B2 (ja) * 2018-03-13 2022-03-09 共立製薬株式会社 反芻動物のネオスポラ感染症に対するワクチン製剤
CN112567017B (zh) * 2018-05-15 2024-08-23 沃尔特及伊莱萨霍尔医学研究院 寄生虫疫苗
CN109825514A (zh) * 2019-01-24 2019-05-31 华中农业大学 田鼠巴贝斯虫gpi10基因及其编码的蛋白和应用
CN110922491B (zh) * 2019-12-17 2021-08-27 河南科技大学 一种肉孢子虫融合抗原、编码基因、间接elisa抗体检测试剂盒及其应用
US12144853B2 (en) 2020-01-13 2024-11-19 University Of Washington Targeted vaccination in the liver

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
WO2000066154A2 (en) * 1999-05-04 2000-11-09 Arch Development Corporation Anti-microbial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756662A (en) * 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
BR9612268A (pt) * 1995-12-22 1999-07-13 Du Pont Método para controlar a express o de uma proteína inseticida método para a produção de baculovírus recombinentes inseticidas células de inseto recombinante inseto transgênio e vetor de expressão de baculovirus recombinante
US6596508B2 (en) * 1999-03-19 2003-07-22 National Research Council Of Canada CRE-inducible expression system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998037185A2 (en) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vectors for controlled gene expression
WO2000066154A2 (en) * 1999-05-04 2000-11-09 Arch Development Corporation Anti-microbial agents, diagnostic reagents, and vaccines based on unique apicomplexan parasite components

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
a low-background inducible promoter system in Leishmaniadonovani. Yan shaofeng.Molecular and biochemical parasitology,Vol.119 No.2. 2002
a low-background inducible promoter system in Leishmaniadonovani. Yan shaofeng.Molecular and biochemical parasitology,Vol.119 No.2. 2002 *

Also Published As

Publication number Publication date
AU2003270274B2 (en) 2009-03-19
CA2498604A1 (en) 2004-04-01
US20050244437A1 (en) 2005-11-03
AU2003270274A1 (en) 2004-04-08
JP2006518184A (ja) 2006-08-10
BR0313994A (pt) 2005-07-19
EP1543028A2 (en) 2005-06-22
WO2004026903A3 (en) 2004-06-03
CN1681842A (zh) 2005-10-12
WO2004026903A2 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
CN100393866C (zh) 减毒活寄生虫疫苗
KR102869944B1 (ko) 조작된 면역자극성 박테리아 균주 및 이의 용도
AU2020229875B2 (en) Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
KR20210091740A (ko) 세포-매개된 종양용해 바이러스 요법용 향상된 시스템
KR20200064980A (ko) 종양 세포에서 면역 조절제 및 항-암 치료제를 생산하도록 프로그램된 미생물
KR20220113943A (ko) 면역자극성 박테리아 전달 플랫폼 및 치료 제품의 전달을 위한 이의 용도
US7026156B1 (en) Diagnostic and protective antigen gene sequences of ichthyophthirius
JP2009077713A (ja) アイメリア・マキシマ（Ｅｉｍｅｒｉａｍａｘｉｍａ）の配偶子母細胞由来の組換え５６及び８２ｋＤａ各抗原をコードする核酸及びその使用
Kaneko et al. Disruption of the C-terminal region of EBA-175 in the Dd2/Nm clone of Plasmodium falciparum does not affect erythrocyte invasion
JP3215692B2 (ja) 組み換えコクシジウム症ワクチン
WO2000046381A1 (en) Recombinant expression of heterologous nucleic acids in protozoa
US7326568B2 (en) Recombinant expression of heterologous nucleic acids in protozoa
KR0152245B1 (ko) 에이메리아 테넬라 왁찐
US5643718A (en) Transfection and genetic manipulations in obligate intracellular parasites
EP2598163B1 (en) Recombinant trypanosoma theileri parasite
WO2008115852A1 (en) A transfection system for perkinsus species
JP2004520277A (ja) 胞子虫網（ａｐｉｃｏｍｐｌｅｘａｎ）寄生虫からの細胞侵入因子に基づくワクチン
Wand et al. Variant surface glycoprotein synthesis and cell cycle progression in Trypanosoma brucei
Matthews Metacyclic VSG Gene Activation in Trypanosoma brucei rhodesiense
Ghoneim Available online at https://djs. journals. ekb. eg
Ghoneim Recombinant expression of the rhoptry protein Clag3. 1 as a green fluorescent chimeric protein in Plasmodium falciparum
JP2002101885A (ja) マダイイリドウイルスのウイルス中和・感染防御関連タンパク質をコードするｄｎａ
Belperron Plasmodium falciparum SERA protein transgenics used in the study parasite immunobiology and drug resistance
Cook et al. AMOEBIC GILL DISEASE (AGD) VACCINE DEVELOPMENT PHASE II–MOLECULAR BASIS OF HOST PARASITE INTERACTIONS IN AMOEBIC GILL DISEASE
Lo Expression of a major surface antigen of Toxoplasma gondii (P30) in Escherichia coliandArabidopsis thaliana

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: INTERVET INTERNATIONAL CO., LTD.

Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP.

Effective date: 20061208

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20061208

Address after: Holland Haier box

Applicant after: Intervet International Co., Ltd.

Address before: Holland Arnhem

Applicant before: Akzo Nobel N. V.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080611

Termination date: 20120919